Drug Trial Radar · NCT00374322
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Last checked: Nov 20, 2026Latest source record: Aug 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,166
Actual
Start
Aug 2006
Primary completion
Sep 2011
Study completion Jul 2013
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 11, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.
Conditions
- Neoplasms, Breast
Interventions
lapatinibDrug
Lapatinib 1500 mg (6 tablets) daily for 12 months
placeboOther
6 tablets daily for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])Time frame: From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])
Locations
439 sites in 33 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tuscaloosa, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Sedona, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Gilroy, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
La Verne, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
Rancho Mirage, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Fairfield, Connecticut
GSK Investigational Site
Norwalk, Connecticut
GSK Investigational Site
Torrington, Connecticut
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Boynton Beach, Florida
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
New Port Richey, Florida
GSK Investigational Site
Ocala, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Port Saint Lucie, Florida
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Marietta, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Joliet, Illinois
GSK Investigational Site
Park Ridge, Illinois
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Ames, Iowa
GSK Investigational Site
Sioux City, Iowa
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Louisville, Kentucky
GSK Investigational Site
Marrero, Louisiana
Showing 40 of 439 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.